Injections of Dysport (botulinum toxin) provide multiple benefits for children with leg spasticity caused by cerebral palsy (CP), according to a clinical trial that assessed treatment with repeat injections over the course of a year. The treatment did not only lower spasticity, but also improved measures of muscle tone…
The U.S. Food and Drug Administration (FDA) has expanded approval of Dysport (abobotulinumtoxinA) for the treatment of lower limb spasticity in adults based on its supplemental Biologics License Application (sBLA), according to therapy developer Ipsen Biopharmaceuticals. Lower limb spasticity is a condition that affects many people in the United…
Having a clown around can help take some of the sting out of the injections that children with cerebral palsy (CP) receive, a study indicates. The research, “Clown-Care Reduces Pain In Children With Cerebral Palsy Undergoing Recurrent Botulinum Toxin Injections: A Quasi-Randomized Controlled Crossover Study,” was published in the…
An enzyme called hyaluronidase might reduce muscle stiffness in people with cerebral palsy and other neurological injuries, without causing the muscles to become weak — a major drawback of current approaches to treating muscle stiffness. The study, “Human Recombinant Hyaluronidase Injections For Upper Limb Muscle Stiffness in…
Ipsen Biopharmaceuticals reported additional results from an extended clinical trial evaluating the safety and effectiveness of Dysport (botulinum toxin type A) in children with lower limb spasticity due to cerebral palsy at this year’s meeting of the American Academy of Cerebral Palsy and Developmental Medicine Sept. 20-24 in Hollywood, Florida. The…
The U.S. Food and Drug Administration (FDA) approved Ipsen Biopharmaceuticals’ supplemental Biologics License Application for Dysport (abobotulinumtoxinA) injection for the treatment of lower limb spasticity in pediatric patients ages 2 and older. Patients with spasticity have an abnormal increase in muscle tone or stiffness, which may interfere with movement or…
Surgery may be used to ease, relieve, or treat various symptoms or limitations that cerebral palsy (CP) causes. It can make the condition more manageable, prevent future complications, and improve patients’ quality of life. Children with CP usually have poor muscle and bone growth. Weak…
There is limited evidence supporting the current therapies used to manage pain in children and adolescents with cerebral palsy, according to a recent study. Further research to explore multidisciplinary interventions for chronic pain and pain secondary to dystonia — involuntary muscle contractions — along with a standardized approach to pain…
Xeomin (incobotulinumtoxinA) has been approved by the U.S. Food and Drug Administration to treat chronic sialorrhea, or excessive drooling, a condition often experienced by people with cerebral palsy. Merz Neurosciences, a division of Merz North America, announced that its supplemental biologics license application (sLBA)…
Pain severity in teenagers with cerebral palsy (CP) is associated with more motor impairment and has negative effects on general health and quality of life, a study has found. The study, “Factors associated with pain in adolescents with bilateral cerebral palsy,” was published in the journal Developmental Medicine &…